Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure

Breast Cancer Research and Treatment

Volumn 85, Issue 1, 2004, Pages 31-51

  Guo, Baoqing ^a   Villeneuve, David J ^a   Hembruff, Stacey L ^a   Kirwan, Angie F ^a   Blais, David E ^b   Bonin, Michel ^a   Parissenti, Amadeo M ^a,b,c  

^a SUDBURY REGIONAL HOSPITAL   (Canada)

^b LAURENTIAN UNIVERSITY   (Canada)

^c Off of the Chair in Cancer Research   (Canada)

Author keywords

BCRP; Breast cancer; Cross resistance; Doxorubicin; Induction; P glycoprotein; Paclitaxel; Procaspase 9

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; BREAST CANCER RESISTANCE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CASPASE 3; CASPASE 9; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKERATIN 20; CYTOKERATIN 7; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPITHELIAL MEMBRANE ANTIGEN; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN P; IRINOTECAN; KERATIN; METHOTREXATE; PACLITAXEL; PROCASPASE 9; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; PROTEIN S 100; TUMOR MARKER; UNCLASSIFIED DRUG; VALSPODAR; VIMENTIN; VINBLASTINE;

ARTICLE; BREAST TUMOR; CELL STRAIN MCF 7; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACCUMULATION; DRUG SENSITIVITY; DRUG UPTAKE; FLOW CYTOMETRY; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICROTUBULE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CASPASE 9; CASPASES; CELL LINE, TUMOR; DOXORUBICIN; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PACLITAXEL;

EID: 1842554867     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000021046.29834.12     Document Type: Article

References (77)

1. Zijlstra JG, de Jong S, de Vries EG, Mulder NH: Topoisomerases, new targets in cancer chemotherapy. Med Oncol Tumor Pharmacother 7: 11-18, 1990
2. Nielsen D, Jensen JB, Dombernowsky P: Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 8: 1806-1810, 1990
3. Richardson DS, Johnson SA: Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Rev 11: 201-223, 1997
4. Capranico G, Tinelli S, Zunino F: Formation, resealing and persistence of DNA breaks produced by 4-demethoxydaunorubicin in P388 leukemia cells. Chem Biol Interact 72: 113-123, 1989
5. Wu XX, Mizutani Y, Kakehi Y, Yoshida O, Ogawa O: Enhancement of Fas-mediated apoptosis in renal cell cacinoma cells by adriamycin. Cancer Res 60: 2912-2918, 2000
6. Yamaoka M, Yamaguchi S, Suzuki T, Okuyama M, Nitobe J, Nakamura N, Mitsui Y, Tomoike H: Apoptosis in rat cardiac myocytes induced by Fas ligand: priming for Fas-mediated apoptosis with doxorubicin. J Mol Cell Cardiol 32: 881-889, 2000
7. Chazard M, Pellae-Cosset B, Garet F, Soares JA, Lucidi B, Lavail Y, Lenaz L: [Taxol (paclitaxel), first molecule of a new class of cytotoxic agents: taxanes]. Bull Cancer 81: 173-181, 1994
8. Arioka H, Saijo N: [Microtubules and antineoplastic drugs]. Gan To Kagaku Ryoho 21: 583-590, 1994
9. Distefano M, Scambia G, Ferlini C, Gaggini C, De Vincenzo R, Riva A, Bombardelli E, Ojima I, Fattorossi A, Panici PB, Mancuso S: Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int J Cancer 72: 844-850, 1997
10. Moos PJ, Fitzpatrick FA: Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 95: 3896-3901, 1998
11. Citron M, Berry D, Cirrincione C, Hudis C, Winer E, Gradishar W, Davidson N, Martino S, Livingston R, Ingle J, Perez E, Carpenter J, Hurd D, Holland J, Smith B, Sartor C, Leung E, Abrams J, Schilsl R, Muss H, Norton L: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 8: 1431-1439, 2003
12. Berg CD, Swain SM: Results of concomitantly administered chemoradiation for locally advanced noninflammatory breast cancer. Semin Radiat Oncol 4: 226-235, 1994
13. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, Frye D, Hortobagyi GN: Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 40: 321-329, 1997
14. Crown J: Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer. Oncologist 6 (Suppl 3): 17-21, 2001
15. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162, 1976
16. Beck WT, Mueller TJ, Tanzer LR: Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 39: 2070-2076, 1979
17. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line [see comments]. Science 258: 1650-1654, 1992
18. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JR, Hickson ID: Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51: 6592-6595, 1991
19. Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G: Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 52: 1666-1674, 1992
20. Balcer-Kubiczek EK, Yin J, Lin K, Harrison GH, Abraham JM, Meltzer SJ: p53 mutational status and survival of human breast cancer MCF-7 cell variants after exposure to X rays or fission neutrons. Radiat Res 142: 256-262, 1995
21. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811-814, 1996
22. Cai Z, Stancou R, Korner M, Chouaib S: Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF-7 tumor cells. Int J Cancer 68: 535-546, 1996
23. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH: Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 261: 15544-15549, 1986
24. Batist G, Behrens BC, Makuch R, Hamilton TC, Katki AG, Louie KG, Myers CE, Ozols RF: Serial determinations of glutathione levels and glutathione-related enzyme activities in human tumor cells in vitro. Biochem Pharmacol 35: 2257-2259, 1986
25. Harris AL, Hochhauser D: Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 31: 205-213, 1992
26. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP: Taxol: mechanisms of action and resistance. In: Proceedings of the Second National Cancer Institute Workshop on Taxol an Taxus, J Natl Cancer Inst Monogr 15, Washington US Dept of Health and Human Services, 1993, pp 55-61
27. Cabral F, Abraham I, Gottesman MM: Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in alpha-tubulin. Proc Natl Acad Sci USA 78: 4388-4391, 1981
28. Schibler MJ, Huang B: The colR4 and colR15 beta-tubulin mutations in Chlamydomonas reinhardtii confer altered sensitivities to microtubule inhibitors and herbicides by enhancing microtubule stability. J Cell Biol 113: 605-614, 1991
29. Anand S, Penrhyn-Lowe S, Venkitaraman A: AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3: 51-62, 2003
30. Wahl A, Donaldson K, Fairchild C, Lee F, Foster S, Demer G, Galloway D: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2: 72-79, 1996
31. Basu A, Haldar S: Identification of a novel Bcl-xL phosphorylation site regulation the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Lett 538: 41-47, 2003
32. Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli Ferrandina G, Gallo D, Ranelletti F, Scambia G: Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol 64: 51-58, 2003
33. Clark A, West K, Streicher S, Dennis P: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1: 707-717, 2002
34. Seidman AD, Norton L, Reichman BS, Crown JP, Yao TJ, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A: Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Semin Oncol 20: 40-45, 1993
35. Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943-1951, 1993
36. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18: 724-733, 2000
37. Chadderton A, Villeneuve DJ, Gluck S, Kirwan-Rhude AF, Gannon BR, Blais DE, Parissenti AM: Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells. Breast Cancer Res Treat 59: 231-244, 2000
38. Elias, Jules M: Immunohistopathology: A Practical Approach to Diagnosis. Vol. 357 American Society of Clinical Pathology Press, Chicago, USA, 1990
39. Shain KH, Dalton, WS: Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther 1: 69-78, 2001
40. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE: Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 46: 5125-5130, 1986
41. Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, Ponnathpur V, Tourkina E, Ibrado AM, Bullock G: Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 8: 465-475, 1994
42. Li D, Jang S, Kim J, Wientjes M, Au J: Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res 20: 45-50, 2003
43. Ueda K, Cardarelli C, Gottesman MM, Pastan I: Expression of a full-length cDNA for the human 'MDR1' gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84: 3004-3008, 1987
44. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F: In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51: 4226-4233, 1991
45. Jachez B, Nordmann R, Loor F: Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J Natl Cancer Inst 85: 478-483, 1993
46. Jette L, Murphy GF, Beliveau R: Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment. Int J Cancer 76: 729-737, 1998
47. Cabot MC, Giuliano AE, Han TY, Liu YY: SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res 59: 880-885, 1999
48. Lage H, Dietel M: Effect of the breast-cancer resistance protein on atypical multidrug resistance. Lancet Oncol 1: 169-175, 2000
49. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross D, Miyake K, Resau J, Bates S: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113: 2011-2021, 2000
50. Robey R, Medina-Perez W, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz A, Ross D, Bates S: Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7: 145-152, 2001
51. Rabindran S, Ross D, Doyle L, Yang W, Greenberger L: Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60: 47-50, 2000
52. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95: 15665-15670, 1998
53. Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B: Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clin Cancer Res 7: 3874-3883, 2001
54. Marks DC, Su GM, Davey RA, Davey MW: Extended multidrug resistance in haemopoietic cells. Br J Haematol 95: 587-595, 1996
55. Gosland MP, Gillespie MN, Tsuboi CP, Tofiq S, Olson JW, Crooks PA, Aziz SM: Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine. Cancer Chemother Pharmacol 37: 593-600, 1996
56. Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI: Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56: 1091-1097, 1996
57. Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM, Giaccone G: Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 5: 249-255, 1998
58. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV: Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5: 3445-3453, 1999
59. Ikubo S, Takigawa N, Ueoka H, Kiura K, Tabata M, Shibayama T, Chikamori M, Aoe K, Matsushita A, Harada M: In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines. Anticancer Res 19: 3985-3988, 1999
60. NicAmhlaoibh R, Heenan M, Cleary I, Touhey S, O'Loughlin C, Daly C, Nunez G, Scanlon KJ, Clynes M: Altered expression of mRNAs for apoptosis-modulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expresses mdr1 mRNA. Int J Cancer 82: 368-376, 1999
61. Burns BS, Edin ML, Lester GE, Tuttle HG, Wall ME, Wani MC, Bos GD: Selective drug resistant human osteosarcoma cell lines. Clin Orthop 259-267, 2001
62. Zhou J, Cheng SC, Luo D, Xie Y: Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line. Biochem Biophys Res Commun 280: 1237-1242, 2001
63. Combates NJ, Rzepka RW, Chen YN, Cohen D: NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter. J Biol Chem 269: 29715-29719, 1994
64. Devarajan E, Chen J, Multani AS, Pathak S, Sahin AA, Mehta K: Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. Int J Oncol 20: 913-920, 2002
65. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH: Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 261: 15544-15549, 1986
66. Scudiero DA, Monks A, Sausville EA: Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen [letter]. J Natl Cancer Inst 90: 862, 1998
67. Broxterman H, Lankelma J, Pinedo H, Eekman C, Wahrer D, Ossenkoppele G, Schuurhuis G: Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia. Leukemia 11: 1110-1118, 1997
68. Cabot MC, Han TY, Giuliano AE: The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation. FEBS Lett 431: 185-188, 1998
69. Bezombes C, Maestre N, Laurent G, Levade T, Bettaieb A, Jaffrezou JP: Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB J 12: 101-109, 1998
70. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH: The mouse Bcrpl/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59: 4237-4241, 1999
71. Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M, Takebayashi Y: Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 92: 452-458, 2001
72. Borst P, Schinkel AH: Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet 13: 217-222, 1997
73. Wu GS, Ding Z: Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 21: 1-8, 2002
74. Perkins CL, Fang G, Kim CN, Bhalla KN: The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res 60: 1645-1653, 2000
75. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M: Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15: 1796-1802, 1997
76. Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL: Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 93: 787-795, 1999
77. Villeneuve DJ, Hembruff SL, Kirwan AF, Parissenti AM: cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals drug-specific changes in gene expression accompanying the establishment of drug resistance, 2004 (in preparation)